MedTrace Logo

MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes

NCT04761900 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3372

Last updated 2021-02-21

No results posted yet for this study

Summary

Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis. It helps to increase patient awareness and understanding of fatty liver (FL), for who has high-risk metabolic dysfunction. However, a more simplified and easily applicable definition is needed. It will have an impact on clinical practice, especially in developing countries.

Conditions

  • Metabolic Associated Fatty Liver Disease

Interventions

DIAGNOSTIC_TEST

the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases

Sponsors & Collaborators

  • Ningbo No. 1 Hospital

    lead OTHER

Principal Investigators

  • Chengfu Xu, Dr · First Affiliated Hospital of Zhejiang University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-01
Primary Completion
2019-12-31
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04761900 on ClinicalTrials.gov